BZYR
Burzynski Research Institute, Inc.0.0330
-0.0040-10.8%
Dec 16, 4:00:00 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
No earnings call transcript available
Key Stats
Market Cap
4.34MP/E (TTM)
-Basic EPS (TTM)
-0.01Dividend Yield
0%Recent Filings
10-Q
Q3 FY2026 results
Burzynski Research Institute narrowed its Q3 operating loss to $329K from $352K y/y, trimming R&D expenses 13% to $261K on lower facility costs while G&A rose 33% to $68K from regulatory filings; nine-month loss shrank to $994K from $1.1M y/y. No revenue yet, as expected. Cash ticked up to $2K (from $1K at FY start), propped by $968K in Dr. Burzynski contributions covering $967K operating burn—no debt. IND 43742 stays under full FDA clinical hold, blocking new enrollments. Fully reliant on one funder. Losses match shares outstanding.
10-Q
Q2 FY2026 results
Burzynski Research Institute trimmed its Q2 operating loss to $334K from $370K a year ago, thanks to 8% lower R&D and 15% lighter G&A spend amid fewer regulatory demands; six-month loss eased to $665K from $741K (derived). Cash ticked up to $931 from $847 at fiscal year-end, propped by $144K in founder contributions matching $144K operating burn. No revenue yet. Expenses match net losses exactly. IND 43742 stays under full FDA clinical hold. Dependency on Dr. Burzynski's funding looms large.
8-K
Auditor resigns post-acquisition
Burzynski Research Institute's auditor PKF resigned on July 21, 2025, after its acquisition by another firm, leaving the company without a registered public accounting firm. No disagreements or reportable events occurred over the past two fiscal years and interim period through May 31, 2025. The company plans to appoint a replacement soon. PKF confirmed the disclosures.
10-Q
Q1 FY2026 results
Burzynski Research Institute narrowed its Q1 FY2026 operating loss to $331k from $371k y/y, trimming total expenses 11% to $331k despite R&D up 20% to $270k on FDA-driven personnel and facility costs; G&A plunged 58% to $61k from lower professional fees. No revenue, as expected. Cash dipped to $821 from $847 q/q, with operating cash use slowing to $49k from $60k y/y, offset by $49k capital contribution from Dr. Burzynski. Funding hinges entirely on him. Expenses match net loss. IND 43742 stays under full FDA clinical hold.
10-K
FY2025 results
Burzynski Research Institute posted FY2025 ended February 28, 2025 with no significant operating revenue, funded entirely by Dr. Burzynski's contributions recorded as additional paid-in capital. No quarterly breakdowns disclosed in the 10-K. Clinical trials remain stalled under FDA full clinical hold on IND 43742 since 2017, blocking new enrollments; Phase III for DIPG awaits funding and hold lift. Environmental compliance held steady at $10,000. No employees. FDA holds stall progress.
IPO
Sector
Industry
BBOT
BridgeBio Oncology Therapeutics
11.85-0.15
BCLI
BrainStorm Cell Therapeutics In
0.58+0.03
BIAF
bioAffinity Technologies, Inc.
1.38-0.10
BSEM
BioStem Technologies, Inc.
3.84-0.11
CBIO
Crescent Biopharma, Inc.
12.92-0.29
CNSP
CNS Pharmaceuticals, Inc.
7.39+0.12
CSBR
Champions Oncology, Inc.
6.73-1.14
ENZN
Enzon Pharmaceuticals, Inc.
0.05+0.00
NBTX
Nanobiotix S.A.
22.32+0.18
NTHI
NeOnc Technologies Holdings, In
9.44-0.44